Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00607581
Other study ID # AC-003-IT
Secondary ID RV-AMYL-PI-303
Status Completed
Phase Phase 2
First received January 22, 2008
Last updated February 9, 2012
Start date February 2008
Est. completion date January 2012

Study information

Verified date February 2012
Source IRCCS Policlinico S. Matteo
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Interventional

Clinical Trial Summary

The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that produce the light-chain forming the amyloid deposits. The plasma cells can be killed and their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide, steroids, such as dexamethasone, and drugs that stimulate the immune system, such as lenalidomide.

The present trial studies the efficacy and safety of the combination of cyclophosphamide, lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated and need further therapy.


Description:

This study will include previously treated patients with AL amyloidosis.

Primary objectives to determine the hematologic and organ response rate to the association of cyclophosphamide, lenalidomide and dexamethasone (CLD).

Secondary objectives

- to determine the safety of CLD,

- to determine time to response to CLD,

- to determine the duration of response to CLD,

- to assess survival of AL amyloidosis patients treated with CLD.

Patients receive 28-day cycles cyclophosphamide on days 1, 8 and 15, oral lenalidomide on days 1-21 and oral dexamethasone on days 1, 8, 15, and 22.

Up to 9 courses can be performed until one of the following endpoints is met:

- completion of cycle 9,

- complete hematologic remission observed after cycle 3 or 6,

- partial hematologic response associated with organ response after cycle 6.

- no response at cycle 3 or 6. After completion of study treatment, patients are followed every 3 months for up to 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date January 2012
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

- Diagnosis of AL amyloidosis.

- Evidence of a monoclonal light chain at serum and/or urine immunofixation electrophoresis.

- Elevated circulating free light chain (of the type identified by immunofixation) above the upper limit of the normal range and abnormal kappa/lambda ratio.

- Previously treated and requiring further treatment.

- Symptomatic organ involvement.

- Bone marrow plasma cell <30%.

- Echocardiographic ejection fraction >40%.

- Troponin I <0.1 ng/mL.

- Hemoglobin >10 g/dL.

- Absolute neutrophil count >1500/uL.

- Platelet count >140000/uL.

- Total bilirubin <2.5 mg/dL.

- Alkaline phosphatase <4 x upper reference limit (u.r.l.).

- ALT <3 x u.r.l..

- Glomerular filtration rate >30 mL/min.

- Performance status ECOG 1-3.

- Female subjects of childbearing potential must have two negative pregnancy tests prior to starting study drug.

Exclusion Criteria:

- Prior treatment with the association of cyclophosphamide, lenalidomide and dexamethasone or with lenalidomide.

- Requirement for other concomitant chemotherapy, immunotherapy or radiotherapy, or any investigational ancillary therapy.

- Presence of other active malignancies, with the exception of nonmelanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate specific antigen is within normal limits.

- Clinically overt multiple myeloma.

- Uncontrolled infection.

- New York Heart Association (NYHA) class 4 heart failure.

- Enzyme documented myocardial infarction within 6 months before enrollment.

- Grade 2 or 3 atrioventricular block (Mobitz type I is permitted).

- Repetitive ventricular arrhythmias at 24 h Holter electrocardiogram in spite of treatment with amiodarone.

- Supine systolic blood pressure <90 mmHg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure on standing of >20 mmHg in spite of being treated for orthostatic hypotension.

- Prior history of thrombosis or venous thromboembolism or pulmonary embolism. Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency.

- Indication to receive clopidogrel, ticlopidine or warfarin.

- Factor X level <20%.

- Poorly controlled diabetes mellitus (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months).

- Previous or ongoing psychiatric illness (with the exclusion of reactive depression).

- Pregnant or nursing women.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cyclophosphamide
cyclophosphamide: 500 mg orally on days 1, 8, 15
lenalidomide
lenalidomide: 15 mg orally on days 1-21
dexamethasone
dexamethasone: 40 mg orally on days on days 1, 8, 15, 22

Locations

Country Name City State
Italy Amyloidosis Research and Treatment Center - Fondazione IRCCS Policlinico San Matteo Pavia

Sponsors (2)

Lead Sponsor Collaborator
IRCCS Policlinico S. Matteo Celgene Corporation

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15;109(2):465-70. Epub 2006 Sep 28. — View Citation

Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006 Oct 15;108(8):2520-30. Epub 2006 Jun 22. Review. — View Citation

Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005 Apr 1;105(7):2949-51. Epub 2004 Nov 30. — View Citation

Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 Jan 15;109(2):492-6. Epub 2006 Sep 7. — View Citation

Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007 Jan 15;109(2):457-64. Epub 2006 Sep 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary hematologic response rate at 3 months No
Secondary organ response rate at 3 months No
Secondary time to response every 28 days No
Secondary time to progression every 3 months for 3 years No
Secondary survival up to 3 years after treatment discontinuation No
Secondary toxicity continuous during treatment Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
Completed NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Phase 2
Completed NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Phase 2
Completed NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Phase 2
Completed NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Phase 1/Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Active, not recruiting NCT03201965 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Phase 3
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02574676 - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. N/A
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT01406314 - SAP Depleter Dose Assessment Study in Patients Phase 1
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Active, not recruiting NCT05235269 - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis Phase 2
Active, not recruiting NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Phase 1/Phase 2